COCHLEAR Aktie

 

Let's see what the broker is saying about this blue chip. The post What are Cochlear shares worth according to Macquarie? appeared first on The Motley Fool Australia....

Um den gesamten Artikel unter asia.nikkei.com zu lesen, klicken Sie bitte auf die Überschrift...

Upgradeable Firmware: The Cochlear™ Nucleus® Nexa™ System features upgradeable firmware on the implant – an industry first, allowing recipients to access future innovation through firmware updates. Smallest Sound Processor: The new Nucleus 8 Nexa Sound Processor, with the new Power......

These shares are having a good time on hump day. But why? The post Why Beach Energy, Boss Energy, Cochlear, and Light & Wonder shares are pushing higher appeared first on The Motley Fool Australia....

Macquarie has released a new note on Cochlear following the company's FY25 profit guidance change. The post Does Macquarie think Cochlear shares are a buy, hold, or sell? appeared first on The Motley Fool Australia....

Investors haven't responded positively to this update. Let's dig deeper into it. The post Cochlear shares sink 9% on guidance downgrade appeared first on The Motley Fool Australia....

ST. PAUL, Minn., June 11, 2025 /PRNewswire/ -- iotaMotion, Inc., a leader in robotic-assisted systems for cochlear implant surgery, today announced the issuance of U.S. Patent No. 12,311,173. This new patent strengthens iotaMotion's intellectual property portfolio and supports the......

White Bear Lake, Minnesota--(Newsfile Corp. - June 10, 2025) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devi......

NEW Baha® 7 Sound Processor: First in bone conduction to enable Bluetooth® LE Audio* and Auracast™ broadcast audio streaming capabilities1,2. NEW Baha SoundBand™: Improved look and fitting options over current Baha Softband to help children with hearing loss thrive. NEW Bluetooth™ LE......

Let's see what analysts are saying about this blue chip. The post Down 15% since January, are Cochlear shares now a buy? appeared first on The Motley Fool Australia....

ST. PAUL, Minn., May 13, 2025 /PRNewswire/ -- iotaMotion, Inc., a leader in robotic-assisted systems for cochlear implant surgery, today announced the first use of the iotaSOFT® Insertion System outside of the United States. The technology is in use as a pre-market clinical investigation......

As the Nordic region's largest healthcare market and a leading life science nation, Sweden is an attractive environment for healthtech companies that want to scale. And Gothenburg offers a compelling entry point. The region features one of Europe's largest university hospitals and excels in life science. It has an exciting mix of large global companies like AstraZeneca, Getinge, Mölnlycke Health Care, Cochlear and Essity, and a strong startup scene. The spirit of collaboration and sustainability credentials make it a hotspot for health innovation. On 7-9 April, around 30 innovative...

Australia's hearing implant giant Cochlear (ASX:COH) has clarified an April 3 release,…...

Will the company escape from the tariffs? Let's find out. The post How are Cochlear shares impacted by Trump's tariffs? appeared first on The Motley Fool Australia....

Company Provides Corporate Update that Includes Information on its Progress Enrolling Subjects in its Pivotal Clinical Study for Breakthrough Device, the Fully Implanted Acclaim® Cochlear ImplantW......

Das Instrument OC5 AU000000COH5 COCHLEAR LTD EQUITY wird ex Dividende/Zinsen gehandelt am 20.03.2025 The instrument OC5 AU000000COH5 COCHLEAR LTD EQUITY has its ex-dividend/interest day on 20.03.2025...

Das Instrument OC5 AU000000COH5 COCHLEAR LTD EQUITY wird cum Dividende/Zinsen gehandelt am 19.03.2025 und ex Dividende/Zinsen am 20.03.2025 The instrument OC5 AU000000COH5 COCHLEAR LTD EQUITY has its pre-dividend/interest day on 19.03.2025 and its ex-dividend/interest day on 20.03.2025...

Enrolled first cohort into SENS-501's Phase 1/2 clinical trial, Audiogene, and received a positive DMC recommendation; enrollment of second cohort and KOL event to present new data expected during H1 2025 Primary and secondary endpoints achieved in SENS-401's Phase 2a Proof of Concept study for the preservation of residual hearing following cochlear implantation; business development discussions ongoing End of enrollment in SENS-401's Phase 2a Proof of Concept study in Cisplatin-Induced Ototoxicity, NOTOXIS; topline data to be reported by end of Q4 2025 Strengthened balance sheet and shareholder registry via capital increases raising €65.5m from top tier U.S. and European healthcare dedicated institutional investors Cash and short-term deposits of €77m finance the Company until end of Q1 2026 MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat ...

LONE TREE, Colo., March 3, 2025 /PRNewswire/ -- In celebration of World Hearing Day, Cochlear, the global leader in implantable hearing solutions, is proud to announce that it has been named the number one most trustworthy company in the healthcare industry by Newsweek in its 2024......

LONE TREE, Colo., Feb. 25, 2025 /PRNewswire/ -- In celebration of International Cochlear Implant Day, Cochlear North America is thrilled to announce the winners of 2025 annual Cochlear Academic Scholarships. Eight outstanding recipients of either the Cochlear™ Nucleus® Implant, Cochlear......